<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014637</url>
  </required_header>
  <id_info>
    <org_study_id>RV4104A 2008 548</org_study_id>
    <nct_id>NCT01014637</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis</brief_title>
  <acronym>ONICO</acronym>
  <official_title>A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Dermo Cosmetique</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quanta Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pierre Fabre Dermo Cosmetique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate and compare the efficacy of the sequential
      association RV4104A ointment followed by ciclopiroxolamine 1% cream and ciclopirox 8%
      film-forming solution versus amorolfine 5% nail lacquer alone in the treatment of patients
      with dermatophytic onychomycosis (toenail) without matrix involvement.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate and compare the efficacy of the sequential association RV4104A ointment-ciclopiroxolamine 1% cream-ciclopirox 8% film-forming solution versus amorolfine 5% nail lacquer alone in dermatophytic onychomycosis (toenail) without matrix involvement</measure>
    <time_frame>Day 336</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare the local tolerability of the sequential association RV4104A-ciclopiroxolamine-ciclopirox versus amorolfine 5% alone in the treatment dermatophytic onychomycosis (toenail) without matrix involvement</measure>
    <time_frame>Day 21, Day 77, Day 156, Day 262</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare the cost-effectiveness of the sequential association RV4104A ointment-ciclopiroxolamine 1% cream-ciclopirox 8% film-forming solution vs amorolfine 5% alone in the treatment of dermatophytic onychomycosis without matrix involvement</measure>
    <time_frame>Day 336</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare the clinical cure of the sequential association RV4104A ointment-ciclopiroxolamine-ciclopirox 8 versus amorolfine alone in the treatment dermatophytic onychomycosis (toenail) without matrix involvement</measure>
    <time_frame>Day 77, Day 168, Day 252</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Averse Events Reporting</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Amorolfine 5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RV4104A-cylcopiroxolamine-ciclopirox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amorolfine (Antifungal)</intervention_name>
    <description>Treatment with Amorolfine for 36 weeks</description>
    <arm_group_label>Amorolfine 5%</arm_group_label>
    <other_name>Loceryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)</intervention_name>
    <description>Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.</description>
    <arm_group_label>RV4104A-cylcopiroxolamine-ciclopirox</arm_group_label>
    <other_name>RV4104A ointment</other_name>
    <other_name>Mycoster 1%</other_name>
    <other_name>Mycoster 8%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of distal-lateral or lateral subungual onychomycosis of one great
             toenail (the target nail) without matrix involvement

          -  Target nail plate showing between 25% and 60% of clinically infected area

          -  Patient must have at least 2 mm of unaffected proximal target nail area

          -  Target nail infection due exclusively to a dermatophyte (from positive fungal culture
             as reported by the central mycological laboratory)

          -  Female patient of childbearing potential must use an efficient contraceptive method
             for at least 2 months prior to screening visit

          -  Female patient of childbearing potential must have a negative urinary pregnancy test
             at the screening visit

        Exclusion Criteria:

          -  Patient with more than 3 affected nails

          -  Patient with onychomycosis with matrix involvement

          -  Patient with psoriasis, lichen planus or other abnormalities that could result in
             clinically abnormal toenail(s)

          -  Patient with moccasin-type tinea pedis

          -  Patient who has received systemic antifungal therapy or any topical antifungal therapy
             applied to the toenails within 3 months prior to screening visit

          -  Patient with known hypersensitivity to investigational products' ingredient(s)

          -  Patient who is currently participating or who has participated in another clinical
             study within 4 weeks prior to screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carle PAUL, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Purpan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Jacques VOISARD, MD</last_name>
    <phone>+33 5 63 58 88 00</phone>
    <email>jean.jacques.voisard@pierre-fabre.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Héla COUBETERGUES</last_name>
    <phone>+ 33 5 61 73 73 38</phone>
    <email>hela.coubetergues@pierre-fabre.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yves LE CORRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Monique CHASSAIN LE LAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Michel DEBARRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Martigues</city>
        <zip>13500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mireille RUER-MULLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles ROSTAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Didier COUSTOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carle PAUL, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <last_update_submitted>November 16, 2009</last_update_submitted>
  <last_update_submitted_qc>November 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Anne-Marie Schmitt, MD</name_title>
    <organization>Pierre Fabre Dermo Cosmetiques</organization>
  </responsible_party>
  <keyword>Dermatomycoses</keyword>
  <keyword>Infection</keyword>
  <keyword>Mycoses</keyword>
  <keyword>Nail diseases</keyword>
  <keyword>Ski diseases</keyword>
  <keyword>Skin diseases/infectious</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Ciclopirox</mesh_term>
    <mesh_term>Amorolfine</mesh_term>
    <mesh_term>Keratolytic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

